Common Stock, $0.0001 par value per share
- Symbol
- NSPR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 8.01, 9.01 · 8-K
InspireMD Inc.
NSPRNASDAQEQUITYCurrent
Results of Operations and Financial Condition · Other Events
Item 2.02 Results of Operations and Financial Condition On November 12, 2026, InspireMD, Inc. (the “Company”) issued a press release announcing its financial and operating results and recent highlights for the three and nine months ended September 30, 2026. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.…
Press release in this filing
InspireMD Reports Third Quarter 2026 Financial Results →Company context
InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.
Current securities
Registered securities in this filing
InspireMD, Inc. · 8-K · Filed 2026-11-12
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item
2.02 Results of Operations and Financial Condition
On
November 12, 2026, InspireMD, Inc. (the “Company”) issued a press release announcing its financial and operating results
and recent highlights for the three and nine months ended September 30, 2026. A copy of this press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
In
accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to
this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference
into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such filing.
Item 8.01Item 8.01 - Other Events
Item
8.01 Other Events
Set
forth below are certain financial results that the Company reported for the third quarter ended September 30, 2026:
For
the third quarter of 2026, total revenue was $2,242,000.
As
of September 30, 2026, cash and cash equivalents and marketable securities totaled $19,246,000.
Filed exhibits (1)
Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call today, November 12th, at 4:30pm ET - Miami, FL - November 12, 2026 - InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the three and nine months ended September 30, 2026. Recent Business Highlights: Announced two upcoming scheduled talks featuring the CGuard and the CGuard Prime platforms at VEITH symposium 2026, to be held November 17-21, 2026, in New York. Successfully implemented design changes to the delivery system of the CGuard Prime Carotid Stent System (“CGuard Prime for CAS”), which is approved for use in carotid artery stenting (“CAS”) procedures. The enhanced CGuard Prime for CAS is currently undergoing final validation and performance testing in support of a premarket approval (“PMA”) supplement that the Company expects to submit…
Open exhibit ↗